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Abstract Several clinical trials have shown that the inhaled b2-agonists with long-acting properties, formoterol and
salmeterol, maybe effective in acute exacerbationsofchronicobstructivepulmonarydisease (COPD).However, there is
a greatdealofcontroversyregarding thetimingandoptimaldose of inhaled b2-agonistsinthispathologiccondition.Inthis
double-blind, randomised, crossover study, we have compared the bronchodilating effect and the safety of inhaled for-
moterol administered viaTurbuhaler using either a cumulative dose regimen or the equivalent single dose in16 patients
with acute exacerbations of COPD.On the two consecutive days, the patients received, in a randomised order, each of
the following active dose regimens: (A): 9 + 9 + 18 mg of formoterol viaTurbuhaler (36 mg cumulative delivered dose), or
(B): 36 + 0 + 0 mg of formoterol viaTurbuhaler.The three doses on each treatment day were administered at 30-mm
intervals, withmeasurements beingmade 5 and 30min after each dose.Contemporaneously, we alsomeasured oxygen
saturation by pulse oximetry (SpO2) and pulse rate. Both the high dose and the cumulative one induced a significant
bronchodilation expressed as change in FEV1.The difference between the two regimenswas significant (P=0.0332) only
60min after the first inhalation.The trend of FVC and ICwas similar to that of FEV1. All treatment regimens were well
tolerated and no adverse eventswere reported.Neither the administration of the high dose nor that of the cumulative
onemodified heart rate in a significantmanner. Also they did not influence SpO2.This study indicates that a single high
dose of formoterol is as effective as the same dose administered in a cumulativemanner inpatientswith acute exacerba-
tion of COPD. r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1456, available online at http://www.sciencedirect.comINTRODUCTION
There is a great deal of controversy regarding the
timing and optimal dose of inhaled b2-agonists in
the treatmentof acute exacerbations of chronic obstruc-
tive pulmonary disease (COPD).Whereas these agents
once were administered at a moderate dose every hour,
there has been a trend towards increasing frequency
and size of dosing for inhaled b-agonists (1). However,
one study failed to demonstrate a signi¢cant advantage
by giving salbutamol more frequently than once every
60min (2).
Several clinical trials have shown that the inhaled b2-
agonists along with long-acting properties, formoterolReceived 23 September 2002, accepted in revised form 24 September
2002
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E-mail: mcazzola@qubisoft.itand salmeterol, may be e¡ective in acute exacerbations
of COPD when administered as cumulative doses (3^5).
Rodriguez-Roisin (6) correctly de¢ned an acute exacer-
bation of COPD as a sustainedworsening of thepatient’s
condition, from the stable state and beyond normal day-
to-day variations, that is, acute in onset andnecessitating
a change in regular medication in a patient with underly-
ing COPD.The sustainedworsening of the patient’s con-
dition is the best reason to use higher than customary
dosage of long-acting b2-agonists in the treatment of
acute exacerbation of COPD (5). It is nowmandatory to
examine if high doses of these long-acting inhaled b2-
agonists are as e¡ective as the same doses administered
in a cumulativemanner.
In this study, we have compared the bronchodilating
e¡ect and the safety of inhaled formoterol administered
using either a cumulative dose regimen or the equivalent
single dose in patients with acute exacerbations of
COPD.
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Study design
The study was of a double-blind, double-dummy, rando-
mised, crossover design taking place over two consecu-
tive days. Allwork was conducted according to the rules
of the Declaration of Helsinki. An independent review
board for human studies approved the protocol. In-
formedwritten consentwas obtained from the patients.
Patients
Sixteen patients with acute exacerbation of COPD (an-
thonisen exacerbation type I or II), and whowerewilling
to participate, were recruited (Table 1). Their ages ran-
ged from 51 to 77 years. Six of them were smokers and
10 ex-smokers. The diagnosis of COPD was consistent
with the diagnostic standards of European Respiratory
Society (ERS) for the management of COPD (7). Acute
exacerbation was de¢ned as a sustained worsening
of the patient’s condition, from the stable state and be-
yondnormal day-to-day variations [current FEV1 (forced
expiratory volume in one second) always less than
70% of their best], that is, acute in onset and necessitat-
ing a change in regular medication in a patient with
underlying COPD (6). All patients had no indication
for hospitalisation, according to the British Thoracic
Society (BTS) Guidelines (8). The number of patients
for this study was not calculated because it was a pilot
investigation.
A bronchodilator response prior to entry into the
study was not required, but all patients were able to
perform a forced expiratorymanoeuvre. Patients with a
history of asthma, allergic rhinitis, atopy, or with a totalTABLE 1. Demographic data andpulmonary function of patien
Patient Sex Age (years) H
1 M 77
2 F 77
3 M 71
4 M 79
5 M 78
6 M 76
7 M 72
8 M 76
9 M 73
10 M 74
11 M 74
12 M 74
13 M 72
14 M 69
15 F 71
16 M 73blood eosinophil count over 400/mm3 were excluded.
Patients were also excluded if they had comorbidities
(such as congestive heart failure or pulmonary embolus)
or complications of COPD (e.g. pneumothorax) as the
aetiology of exacerbation of their symptoms.No patient
was su¡ering from febrile tracheobronchitis.
Additionalmedication
Oral bronchodilators were not permitted during the
study. Short-acting inhaled b2-agonists were permitted
soon after each testwhenrequired. All patients received
a treatmentwith anoral antibiotic (co-amoxiclavor levo-
£oxacin) and an inhaled steroid (budesonide 400mg or
£uticasone 250mg twice daily),
Patients were asked not to consume cola drinks,
co¡ee or tea and not to smoke in the hours before and
during the investigation.
Treatment
On the two consecutive days, the patients received,
in a randomised order, each of the following active dose
regimens:
(A): 9 + 9 + 18mg of formoterol via Turbuhaler (36mg
cumulative delivered dose equivalent to cumulative
metered dose of 48mg).
(B): 36 + 0 + 0mg of formoterol viaTurbuhaler (delivered
dose).
Treatments were double-blinded, using Turbuhaler
placebo inhalers; active inhalation was performed ¢rst.
Patients always inhaled four consecutive doses. All inha-
lations were made by administering either formoterol
(9mg/inhalation) or placebo.ts
eight (cm) Weight (kg) Smokinghabit
170 71 ex;50 p/y
159 77 4die; 45 p/y
170 69 ex; 44 p/y
157 62 ex; 60 p/y
175 65 ex;39 p/y
174 80 ex; 50 p/y
173 90 ex; 40 p/y
172 62 10 die; 45 p/y
160 73 ex; 40 p/y
162 74 ex; 60 p/y
155 74 ex; 40 p/y
170 74 ex; 30 p/y
164 60 15 die, 25p/y
167 74 ex,40 p/y
160 65 12 die, 20 p/y
172 73 ex,45p/y
FIG. 1. Changes in FEV1 induced by the inhalation of a single
36 mg dose of formoterol Turbuhaler or the same dose adminis-
tered in a cumulativemanner.Values aremean7S.E.
FIG. 2. Changesin ICor FVCinducedby theinhalationof a sin-
gle 36 mgdose of formoterol Turbuhaleror the same dose admi-
nistered in a cumulativemanner.Values aremean7S.E.
460 RESPIRATORYMEDICINEEight patients received treatment (A) on the ¢rst day
and treatment (B) on the second day, while the other
eight received treatment (B) on the ¢rst day and treat-
ment (A) on the second day.
The three doses on each treatment day were adminis-
tered at 30-mm intervals, with measurements being
made 5 and 30min after each dose.
Spirometric testing was performed according to the
procedures described in theAmericanThoracic Society’s
(ATS) 1987 update (9).Two acceptable forced expiratory
manoeuvres were performed. The highest FVC (forced
vital capacity), IC (inspiratory capacity) and FEV1, ob-
tained from one of the curves, were kept for analysis.
Contemporaneously, we also measured oxygen satura-
tionbypulse oximetry (SpO2) andpulserate.Pulse oxime-
try was performedwith the patient breathing room air.
Statistics
The maximum FEV1 value during the dose^response
curve to formoterol or salmeterolwas chosen as the pri-
mary outcome variable to compare the two treatments.
Spirometric data, heart rate and SpO2 values for each
treatment were analysed using the Student’s t-test for
paired variables. Mean responses were also compared
bymultifactorial analysis of variance (ANOVA) to estab-
lish any signi¢cant overall e¡ect between the two treat-
ments. In the presence of a signi¢cant overall ANOVA,
Duncan’s multiple range testing with 95% con¢dence
limitswas used to Identify where di¡erenceswere signif-
icant. A probability level of Po0.05 was considered
as signi¢cant for all tests. All data analysis were per-
formed using computer software (GB-STAT,Version 8.0,
Dynamic Microsystems, Inc, Silver Spring, MD 20904,
U.S.A).
RESULTS
All patients completed the two-day study.No signi¢cant
di¡erences occurred between the baseline spirometric
values of the two treatment groups for FEV1 [mean dif-
ference = 0.015 l (95% CI:0.0301to 0.061l);P=0.496].
Themeanchanges in FEV1frombaseline for each treat-
meht regimen are shown in Fig.1.Both the high dose and
the cumulative one have induced a signi¢cant bronchodi-
lation, expressed as change in FEV1 [mean increases
(95% CI) in litres 5, 30, 35, 60, 65 and 90min after the
inhalation of the high dose: 0.117 (0.080^0.154), 0.134
(0.093^0.174), 0.139 (0.100^0.177), 0.179 (0.138^0.219),
0.201 (0.154^0.249), 0.179 (0.145^0.214); at the same times
after inhalation of the cumulative dose: 0.099 (0.066^
0.133), 0.110 (0.064^0.156), 0.154 (0.097^0.212), 0.141
(0.096^0.186), 0.191 (0.153^0.229), 0.193 (0.162^0.223)].
In particular, for the cumulative treatment regimen,
each new dose produced an increase in FEV1 suggestingthat the dose^response plateau had not been reached.
The di¡erencebetween the tworegimenswas signi¢cant
(P=0.0332) only 60min after the ¢rst inhalation. The
trend of FVC and ICwas similar to that of FEV1 (Fig. 2).
All treatmentregimenswerewell tolerated andno ad-
verse events were reported.Neither the administration
of the high dose nor that of the cumulative onemodi¢ed
heart rate in a signi¢cant manner. Also, they did not
in£uence SpO2 (Table 2). Di¡erences between the two
manners of administrationof the samedose of formoterol
were not signi¢cant.
TABLE 2. Changesinpulserate and SpO2 inducedby theinhalationof a single 36mgdoseof formoterol Turbuhaleror the same
dose administered in a cumulativemanner.Values aremean and 95% CI
Pulse rate (beats/mm) 0 mm 5mm 30mm 35mm 60mm 65mm 90mm
Single dose 76.19 77.31 77.00 77.00 78.75 77.69 76.56
69.60 70.81 69.28 70.07 70.91 69.53 68.48
82.78 83.81 84.72 83.93 86.59 85.85 84.65
Cumulative dose 75.94 77.19 76.50 75.75 77.63 75.88 76.50
68.99 70.77 70.24 70.38 72.01 69.55 70.49
82.89 83.61 82.76 81.12 83.24 82.20 82.51
SpO2 (%)
Single dose 94.63 94.13 93.63 94.13 94.38 94.38 94.38
93.71 92.88 92.54 93.17 93.62 93.46 93.40
95.54 95.37 94.71 95.08 95.13 95.29 95.35
Cumulative dose 94.50 94.31 94.38 94.13 93.94 94.13 93.75
93.22 92.81 92.82 92.75 92.56 92.84 92.45
95.78 95.82 95.93 95.50 95.32 95.41 95.05
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This study indicates that a single high dose of formoterol
is as e¡ective as the same dose administered in a cumula-
tivemanner inpatientswith acute exacerbation ofCOPD.
This ¢nding was unexpected considering that it has
been suggested that the use of a cumulative technique
to obtain bronchodilator dose^response curves will
cause a greater response than a non-cumulative techni-
que, because sequential doses of drug will penetrate
further into the lung (10,11). Practically, Britton and
Tatters¢eld observed that the bronchodilator response
to isoprenaline was less when administered as single
doses of10, 20, 80, and 400mg when compared with the
same doses given according to a cumulative regimen in
patientswith asthma (11).Recently, it has been documen-
ted that the e¡ect on FEV1of 400mg inhaled salbutamol
administered viaTurbuhaler using a cumulative dose regi-
men was (also) greater than the equivalent single dose,
always in subjects with asthma (12).
It is di⁄cult to explain the di¡erences between the
responses in patients with acute exacerbation of COPD
that we have observed in this study, and those in
asthmatic subjects documented by other researchers
(10^12).
We could hypothesise that the use of di¡erent
agents induces di¡erent pharmacodynamic behaviours
independently from the treated pathology. In e¡ect,
in vitro estimates suggest that the bronchodilating po-
tency of formoterol may be100^200 times greater than
that of salbutamol on a molar basis (13,14) i.e. about 60^
120 times greater on a weight basis. If this ¢nding is true
also inhumans in vivo, itmeans that 48mgof formoterol is
a more potent dose than 400mg of salbutamol and is
a dose able to induce a fast and generalised bronchodila-
tion. In other words, this dose, whichwe could call ‘‘rela-
tive saturation dose’’, would be great enough to open themajority of those pulmonary areas that arewithout ana-
tomical damage. On the contrary, 400mg of salbutamol
might not be su⁄cient to elicit the same e¡ect and, for
this reason, patients could draw bene¢t from the pro-
gressive opening of new pulmonary areas that is subse-
quent to the inhalation of increasing doses of this
bronchodilator. In e¡ect, as correctly described by Fish-
wick et al. (12), the ¢rst dose partially opens up the con-
stricted lung, but the doseneeded for this ‘‘¢rstmaximal
bronchodilation’’ is far below the doses usually given.The
next dose given will reach ‘‘new’’ areas of the lung and
thus the bronchodilator e¡ect will increase further.
This will result in a dose^response curve that gradually
approaches a maximum.However, we have documented
that there was no signi¢cant di¡erence between FEV1,
IC and FVC values after 48mg formoterol and 800mg
salbutamol in patients su¡ering from acute exacerbation
of COPD (4) when a dose-response curve has been
constructed.
It is also possible that the di¡erence in the treated
pathologymightbe another reason of the di¡erentbeha-
viour between patients with asthma and those su¡ering
from acute exacerbation of COPD. It might be hypothe-
sised that the non-cumulative technique causes a greater
response than the dose^response curves patients with
COPD, contrary to what is observed in asthma because
in COPD air£ow is limited mainly by structural altera-
tions within and around peripheral airways (15). These
anatomic changes prevent access of b-agonists to the
periphery of the lung where the highest concentration
of b-adrenoceptors is found (16). Consequently, better
penetration of aerosol into the airways partially dilated
by preceding treatment is unimportant in this case.On
the contrary, the non-cumulative technique permits the
inhalation of a high amountof drug thatreaches b2-adre-
noceptors which are present also in the larger airways,
and activates a larger number of these receptors.
462 RESPIRATORYMEDICINELeaving out of consideration the reasons that justify
the describedbehaviour in patientswith acute exacerba-
tions of COPD, we must underline that the single high-
dose regimen also seems to be as safe as the cumulative
one.This ¢nding has important clinical implications with
respect to the utilization of bronchodilator aerosols in
the treatment of acute exacerbation of COPD. In fact,
because side e¡ects areminimal, it would be reasonable
to use 36mg of nebulised formoterol as initial therapy of
acute exacerbation of COPD. In our opinion, this posolo-
gic approach is preferable to prescription of the equiva-
lent cumulative dose regimen when it does not involves
additional risks because it simpli¢es the assumption of
bronchodilator. Alternatively, if there are potential risks
for side e¡ects, dose^response titrationwith formoter-
ol would be advantageous although some degree of side
e¡ects from b-agonist use is tolerable in an acute situa-
tion to achieve a critical therapeutic e¡ect (17).
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